Crescita Therpeutc J (TSE:CTX)
TSX:CTX
Top Page
Crescita Therpeutc
(TSX:CTX)
Select Model
Select Model
Rating:74Outperform
Price Target:
C$0.84
▲(78.72% Upside)
Action:UpgradedDate:04/09/26
The score is driven mainly by improving financial performance (profitability rebound and positive free cash flow) alongside a very conservative balance sheet. Valuation is a meaningful positive due to the very low P/E, while technicals are supportive but capped by overbought momentum (high RSI).
Positive Factors
Conservative Balance Sheet
Very low leverage (debt-to-equity ~0.03) provides durable financial flexibility to fund R&D, clinical programs and commercialization without heavy reliance on external debt. This reduces solvency risk, preserves optionality for opportunistic investment or M&A, and supports multi-quarter planning.
Negative Factors
Top-line Inconsistency
TTM revenue contraction after prior growth undermines predictability of revenue expansion. Unstable top-line trends complicate capacity planning, delay margin normalization, and make it harder to model sustainable cash generation, increasing execution risk across future reporting periods.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Very low leverage (debt-to-equity ~0.03) provides durable financial flexibility to fund R&D, clinical programs and commercialization without heavy reliance on external debt. This reduces solvency risk, preserves optionality for opportunistic investment or M&A, and supports multi-quarter planning.
Read all positive factors
Crescita Therpeutc (CTX) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$13.96M
Dividend YieldN/A
Average Volume (3M)12.63K
Price to Earnings (P/E)―
Beta (1Y)-0.78
Revenue Growth26.79%
EPS GrowthN/A
CountryCA
Employees71
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.04
Shares Outstanding18,613,937
10 Day Avg. Volume2,470
30 Day Avg. Volume12,630
Financial Highlights & Ratios
PEG Ratio1.02
Price to Book (P/B)0.58
Price to Sales (P/S)0.43
P/FCF Ratio12.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Crescita Therpeutc Business Overview & Revenue Model
Company Description
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Lice...
Crescita Therpeutc Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
82
Very Positive
Cash Flow
64
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 21.12M | 19.58M | 17.52M | 23.52M | 16.77M |
| Gross Profit | 10.37M | 9.61M | 10.36M | 13.18M | 10.01M |
| EBITDA | 479.00K | -1.33M | 45.00K | 2.09M | 598.00K |
| Net Income | -92.00K | -2.75M | -1.99M | 862.00K | -1.10M |
Balance Sheet | |||||
| Total Assets | 20.33M | 21.78M | 24.60M | 28.48M | 28.92M |
| Cash, Cash Equivalents and Short-Term Investments | 8.58M | 9.27M | 9.38M | 8.24M | 11.33M |
| Total Debt | 334.00K | 834.00K | 1.25M | 1.61M | 2.87M |
| Total Liabilities | 4.75M | 5.95M | 5.78M | 7.39M | 8.40M |
| Stockholders Equity | 15.58M | 15.83M | 18.82M | 21.10M | 20.53M |
Cash Flow | |||||
| Free Cash Flow | 740.00K | 1.54M | 1.94M | -1.25M | -1.94M |
| Operating Cash Flow | 1.07M | 2.73M | 2.08M | -1.02M | -1.60M |
| Investing Cash Flow | -973.00K | -2.02M | -133.00K | -290.00K | -846.00K |
| Financing Cash Flow | -788.00K | -861.00K | -782.00K | -1.85M | -500.00K |
Crescita Therpeutc Technical Analysis
Positive
0.47
Price Trends
0.58
Positive
0.52
Positive
0.50
Positive
Market Momentum
0.05
Positive
78.98
Negative
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CTX, the sentiment is Positive. The current price of 0.47 is below the 20-day moving average (MA) of 0.71, below the 50-day MA of 0.58, and below the 200-day MA of 0.50, indicating a bullish trend. The MACD of 0.05 indicates Positive momentum. The RSI at 78.98 is Negative, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:CTX.
Crescita Therpeutc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | C$470.99M | 10.05 | 24.23% | ― | 94.28% | 5.23% | |
74 Outperform | C$13.96M | -3.14 | 2.92% | ― | 26.79% | ― | |
68 Neutral | C$127.26M | 294.90 | 0.87% | ― | 2.14% | -83.06% | |
55 Neutral | C$215.91M | -3.37 | -238.02% | ― | ― | 21.17% | |
54 Neutral | C$12.73M | -2.12 | -18.39% | ― | 24.30% | -68.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$142.30M | -8.75 | -19.40% | ― | 0.73% | 33.51% |
* Healthcare Sector Average
TSE:CTX
Crescita Therpeutc
0.75
0.21
38.89%
TSE:CPH
Cipher Pharmaceuticals
18.65
7.61
68.93%
TSE:MPH
Medicure
1.22
0.44
56.41%
TSE:MDP
Medexus Pharmaceuticals Inc
3.94
1.82
85.85%
TSE:HLS
HLS Therapeutics Inc
4.55
0.52
12.90%
TSE:CRDL
Cardiol Therapeutics
1.93
0.62
47.33%
Crescita Therpeutc Corporate Events
Business Operations and StrategyDelistings and Listing ChangesFinancial DisclosuresM&A Transactions
Crescita Narrows Losses in 2025 and Agrees to Premium All-Cash Takeover by ClinActiv
Positive
Mar 31, 2026
Crescita Therapeutics reported full-year 2025 revenue of $21.1 million, up from $19.6 million, with gross profit rising and operating expenses slightly lower, resulting in a sharply reduced net loss of $0.1 million and positive adjusted EBITDA. Ma...
Business Operations and StrategyM&A Transactions
Crescita to Be Acquired by ClinActiv in Premium All-Cash Deal
Positive
Mar 16, 2026
Crescita Therapeutics has agreed to be acquired by ClinActiv Holdings in an all-cash transaction under which ClinActiv’s affiliate will purchase all outstanding Crescita shares for a target price of $0.80 per share, subject to working capita...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.